phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2021-1-33-37phgenomics-213Research ArticleПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯPERSONALIZED THERAPYОпыт применения молекулярного профилирования тканей Oncobox у пациентки с рецидивирующим раком эндометрияOncobox molecular profiling for a patient with recurrent endometrial cancerСеряковА. П.SeryakovA. P.

Серяков Александр Павлович, д. м. н., профессор, врач-онколог

Москва

Seryakov Alexander P., Dr. Sci. (Med.), Professor, Oncologist

Moscow

alseryakov@yandex.ruАхмаевР. М.AkhmaevR. M.

Ахмаев Расул Магомедович, врач-онколог

Москва

Akhmaev Rasul M., Oncologist

Moscow

dr.ahmaev23@mail.ruhttps://orcid.org/0000-0002-6589-2164ГурьяноваА. А.GuryanovaA. A.

Гурьянова Анастасия Андреевна, м. н. с., врач-ординатор

Москва

Guryanova Anastasia A., junior researcher, resident physician

Moscow

nt301@yandex.ruПрокофьеваА. А.ProkofievaA. A.

Прокофьева Анастасия Александровна, студентка Института клинической медицины им. Н.В. Склифосовского

Москва

Prokofieva Anastasia A., student

Moscow

nastik4289@yandex.ruМногопрофильный медицинский холдинг «СМ-Клиника»РоссияMultidisciplinary medical holding «CM-Clinic»Russian FederationФедеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И. М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)Russian FederationFederal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation202115092021013337Copyright © Серяков А.П., Ахмаев Р.М., Гурьянова А.А., Прокофьева А.А., 20222022Серяков А.П., Ахмаев Р.М., Гурьянова А.А., Прокофьева А.А.Seryakov A.P., Akhmaev R.M., Guryanova A.A., Prokofieva A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/213Актуальность

Актуальность. Рак эндометрия (РЭ) является наиболее распространённой гинекологической опухолью. Как правило она имеет хороший прогноз, однако в случае рецидива он значительно ухудшается. Эффективность цитотоксической химиотерапии для лечения таких пациентов остаётся низкой.

Цель

Цель. Представить клинический случай, демонстрирующий возможности терапии, проведённой согласно результатам молекулярного профилирования опухоли методами РНК-секвенирования.

Методы

Методы. Проведён анализ данных анамнеза, результатов гистологического и иммуногистохимического исследований, ПЭТ-КТ и картины ультразвукового исследования, данных РНК секвенирования. Оценены результаты терапии, назначенной в соответствии с рейтингом таргетных препаратов, полученных после обработки транскриптомного профиля диагностической платформой Oncobox.

Результаты

Результаты. По результатам экспериментальной терапии второй линии у пациентки был зафиксирован частичный ответ.

Заключение

Заключение. Раннее молекулярное профилирование и назначение терапии в соответствии с его результатами может менять течение заболевания и улучшать качество жизни пациентов.

Relevance

Relevance. Endometrial cancer (EC) is the most common gynecological tumor. As a rule, it has a good prognosis, but in case of relapse, it worsens significantly. The effectiveness of cytotoxic chemotherapy for the treatment of such patients remains low.

Purpose

Purpose. To present a clinical case demonstrating the possibilities of therapy performed according to the results of molecular profiling of the tumor by RNA sequencing methods.

Methods

Methods. Analysis of the anamnesis data, the results of histological and immunohistochemical studies, PET-CT, ultrasound images, and RNA sequencing data was carried out. The results of therapy prescribed in accordance with the rating of targeted drugs obtained after processing the transcriptomic profile by the Oncobox diagnostic platform were evaluated.

Results

Results. After experimental second-line therapy, a partial response was recorded.

Conclusion

Conclusion. Early molecular profiling and therapy assignment in accordance with its results can change the course of the disease and improve the quality of life of patients.

рак эндометриярецидивирующие злокачественные опухолимолекулярное профилированиетранскриптомикаРНК-секвенированиеОнкобоксэкспериментальная терапиямолекулярная диагностикаendometrial cancerrecurrent malignant tumorsmolecular profilingtranscriptomicsRNA sequencingOncoboxexperimental therapymolecular diagnosticsReferencesFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. DOI: 10.1002/ijc.29210Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. DOI: 10.1002/ijc.29210Lacey JV, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer. 2012 Oct 15;131(8):1921–1929. DOI: 10.1002/ijc.27457Lacey JV, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer. 2012 Oct 15;131(8):1921–1929. DOI: 10.1002/ijc.27457Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ostrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988 Feb;57(2):205–212. DOI: 10.1038/bjc.1988.44.Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ostrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988 Feb;57(2):205–212. DOI: 10.1038/bjc.1988.44.Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1110–1116. DOI: 10.1093/jnci/89.15.1110.Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1110–1116. DOI: 10.1093/jnci/89.15.1110.Kaaks R, Lukanova A, Kurzer MS (2002). Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531–1543.Kaaks R, Lukanova A, Kurzer MS (2002). Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531–1543.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569–578. DOI: 10.1016/S0140-6736(08)60269-X.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569–578. DOI: 10.1016/S0140-6736(08)60269-X.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. DOI: 10.1016/0029-7844(94)00383-O.Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. DOI: 10.1016/0029-7844(94)00383-O.Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):341–354. DOI: 10.1053/beog.2000.0180.Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):341–354. DOI: 10.1053/beog.2000.0180.Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001 Nov;83(2):388–393. DOI: 10.1006/gyno.2001.6434.Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001 Nov;83(2):388–393. DOI: 10.1006/gyno.2001.6434.Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat. 2000;5(4):221–231.Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat. 2000;5(4):221–231.Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol Oncol. 2006 Jun;101(3):520–529. DOI: 10.1016/j.ygyno.2006.02.011.Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol Oncol. 2006 Jun;101(3):520–529. DOI: 10.1016/j.ygyno.2006.02.011.Huijgens ANJ, Mertens HJMM. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179-86.Huijgens ANJ, Mertens HJMM. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179-86.Jeppesen MM, Jensen P T, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—A national cohort study. Eur J Cancer. 2016 Dec;69:51–60. DOI: 10.1016/j.ejca.2016.09.033.Jeppesen MM, Jensen P T, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—A national cohort study. Eur J Cancer. 2016 Dec;69:51–60. DOI: 10.1016/j.ejca.2016.09.033.Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, Lawrence M, Kandoth C, Dooling D, Fulton R, Fulton L, Kalicki-Veizer, J,Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, Lawrence M, Kandoth C, Dooling D, Fulton R, Fulton L, Kalicki-Veizer, J,McLellan MD, O’Laughlin M, Schmidt H, Wilson RK, Ye K, Li D, Ally A, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. DOI: 10.1038/nature12113.McLellan MD, O’Laughlin M, Schmidt H, Wilson RK, Ye K, Li D, Ally A, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. DOI: 10.1038/nature12113.Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. DOI: 10.1016/0090-8258(83)90111-7.Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. DOI: 10.1016/0090-8258(83)90111-7.Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol. 2009 Feb;5(1):27–32. DOI: 10.2217/14796694.5.1.27.Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol. 2009 Feb;5(1):27–32. DOI: 10.2217/14796694.5.1.27.Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, Tamura K. Baseline risk of recurrence in stage I–II endometrial carcinoma. J Gynecol Oncol. 2018 Jan;29(1):e9. DOI: 10.3802/jgo.2018.29.e9.Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, Tamura K. Baseline risk of recurrence in stage I–II endometrial carcinoma. J Gynecol Oncol. 2018 Jan;29(1):e9. DOI: 10.3802/jgo.2018.29.e9.Morrow CP, Bundy BN, Kurman RJ, Creasman W T, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol. 1991 Jan;40(1):55–65. DOI: 10.1016/0090-8258(91)90086-k.Morrow CP, Bundy BN, Kurman RJ, Creasman W T, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol. 1991 Jan;40(1):55–65. DOI: 10.1016/0090-8258(91)90086-k.Carey MS, O’Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, Schepansky A, Peloquin A, Lumsden BJ. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage i adenocarcinoma of the endometrium. Gynecol Oncol. 1995 May;57(2):138–144. DOI: 10.1006/gyno.1995.1115.Carey MS, O’Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, Schepansky A, Peloquin A, Lumsden BJ. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage i adenocarcinoma of the endometrium. Gynecol Oncol. 1995 May;57(2):138–144. DOI: 10.1006/gyno.1995.1115.Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000 Jun;182(6):1506–1519. DOI: 10.1067/mob.2000.107335.Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000 Jun;182(6):1506–1519. DOI: 10.1067/mob.2000.107335.Güngördük K, Cuylan ZF, Kahramanoglu I, Oge T, Akbayir O, Dede M, Taşkln S, Ozgul N, Simsek T, Turan H, Gülseren V, Ozdemir A, Meydanll MM, Ayhan A. Risk Factors for Recurrence in Low-Risk Endometrial Cancer: A Case-Control Study. Oncol Res Treat. 2018;41(7-8):466–470. DOI: 10.1159/000488112.Güngördük K, Cuylan ZF, Kahramanoglu I, Oge T, Akbayir O, Dede M, Taşkln S, Ozgul N, Simsek T, Turan H, Gülseren V, Ozdemir A, Meydanll MM, Ayhan A. Risk Factors for Recurrence in Low-Risk Endometrial Cancer: A Case-Control Study. Oncol Res Treat. 2018;41(7-8):466–470. DOI: 10.1159/000488112.Versluis MA, De Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, De Bock GH, Nijman HW. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer. 2015 Sep 1;113(5):786–793. DOI: 10.1038/bjc.2015.268.Versluis MA, De Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, De Bock GH, Nijman HW. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer. 2015 Sep 1;113(5):786–793. DOI: 10.1038/bjc.2015.268.Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U., Azim SA, Müller-Holzner E, Ben-Arie A, Van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Fogel M. L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7;105(15):1142–1150. DOI: 10.1093/jnci/djt144.Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U., Azim SA, Müller-Holzner E, Ben-Arie A, Van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Fogel M. L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7;105(15):1142–1150. DOI: 10.1093/jnci/djt144.Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk- Schulz IM, Jobsen JJ, Creutzberg CL, Smit VTHBM. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer. 2014 Oct;50(15):2602–2610. DOI: 10.1016/j.ejca.2014.07.014.Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk- Schulz IM, Jobsen JJ, Creutzberg CL, Smit VTHBM. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer. 2014 Oct;50(15):2602–2610. DOI: 10.1016/j.ejca.2014.07.014.Werner HMJ, Trovik J, Halle MK, Wik E, Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C, Salvesen HB. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One. 2014 Feb 25;9(2):e90141. DOI: 10.1371/journal.pone.0090141.Werner HMJ, Trovik J, Halle MK, Wik E, Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C, Salvesen HB. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One. 2014 Feb 25;9(2):e90141. DOI: 10.1371/journal.pone.0090141.Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, Kobayashi N, Sudo S, Takeda M, Kaneuchi M, Sakuragi N. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011 Mar 31;22(1):3–8. DOI: 10.3802/jgo.2011.22.1.3.Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, Kobayashi N, Sudo S, Takeda M, Kaneuchi M, Sakuragi N. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011 Mar 31;22(1):3–8. DOI: 10.3802/jgo.2011.22.1.3.Shim SH, Kim DY, Kim HJ, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Stratification of risk groups according to survival after recurrence in endometrial cancer patients. Medicine (Baltimore). 2017 May;96(21):e6920. DOI: 10.1097/MD.0000000000006920.Shim SH, Kim DY, Kim HJ, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Stratification of risk groups according to survival after recurrence in endometrial cancer patients. Medicine (Baltimore). 2017 May;96(21):e6920. DOI: 10.1097/MD.0000000000006920.Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019 Jul;154(1):38–44. DOI: 10.1016/j.ygyno.2019.04.676.Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019 Jul;154(1):38–44. DOI: 10.1016/j.ygyno.2019.04.676.DeVita VT, Lawrence, TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, Wolters Kluwer. 2018. p. 2170–2101.DeVita VT, Lawrence, TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, Wolters Kluwer. 2018. p. 2170–2101.Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol. 2020;2063:235–255. DOI:10.1007/978-1-0716-0138-9_17Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol. 2020;2063:235–255. DOI:10.1007/978-1-0716-0138-9_17Sorokin M, Poddubskaya E, Baranova M, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020;6(2):a004945. Published 2020 Apr 1. DOI:10.1101/mcs.a004945Sorokin M, Poddubskaya E, Baranova M, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020;6(2):a004945. Published 2020 Apr 1. DOI:10.1101/mcs.a004945Poddubskaya E, Bondarenko A, Boroda A, et al. Transcriptomics- Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Front Oncol. 2019;9:1026. Published 2019 Oct 15. DOI:10.3389/fonc.2019.01026Poddubskaya E, Bondarenko A, Boroda A, et al. Transcriptomics- Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Front Oncol. 2019;9:1026. Published 2019 Oct 15. DOI:10.3389/fonc.2019.01026Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol Case Stud. 2019;5(2):a003434. Published 2019 Apr 1. DOI:10.1101/mcs.a003434Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol Case Stud. 2019;5(2):a003434. Published 2019 Apr 1. DOI:10.1101/mcs.a003434Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol. 2018;7:21. Published 2018 Sep 6. DOI:10.1186/s40164-018-0113-xPoddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol. 2018;7:21. Published 2018 Sep 6. DOI:10.1186/s40164-018-0113-xMoisseev A, Albert E, Lubarsky D, Schroeder D, Clark J. Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case. Biomedicines. 2020;8(3):67. Published 2020 Mar 23. DOI:10.3390/biomedicines8030067Moisseev A, Albert E, Lubarsky D, Schroeder D, Clark J. Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case. Biomedicines. 2020;8(3):67. Published 2020 Mar 23. DOI:10.3390/biomedicines8030067

The authors declare that there are no conflicts of interest present.